Aura Biosciences (NASDAQ:AURA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a report published on Monday morning,Benzinga reports. They currently have a $22.00 price target on the stock.

Separately, Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Trading Down 6.7 %

Aura Biosciences stock opened at $7.00 on Monday. The stock has a 50-day moving average price of $7.65 and a 200 day moving average price of $8.66. Aura Biosciences has a 52 week low of $6.33 and a 52 week high of $12.38. The stock has a market cap of $349.66 million, a PE ratio of -4.05 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). On average, equities analysts predict that Aura Biosciences will post -1.66 EPS for the current year.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 23,045 shares of company stock valued at $177,242. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in AURA. BNP Paribas Financial Markets purchased a new stake in shares of Aura Biosciences during the 4th quarter worth about $50,000. China Universal Asset Management Co. Ltd. purchased a new stake in Aura Biosciences during the fourth quarter worth approximately $87,000. ProShare Advisors LLC purchased a new stake in Aura Biosciences during the fourth quarter worth approximately $127,000. Harvest Investment Services LLC acquired a new stake in shares of Aura Biosciences in the fourth quarter worth $133,000. Finally, AlphaQuest LLC purchased a new position in shares of Aura Biosciences in the 4th quarter valued at $136,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.